Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.

Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Abstract Text:

Albert J Molinari,Eugene J Trybulski,Jehan Bagli,Susan Croce,John Considine,Jian Qi,Kadum Ali,William Demaio,Lynne Lihotz,David Cochran,Albert J Molinari,Eugene J Trybulski,Jehan Bagli,Susan Croce,John Considine,Jian Qi,Kadum Ali,William Demaio,Lynne Lihotz,David Cochran,

Small molecule agonists and antagonists of the V(2)-vasopressin receptor have been discovered and have undergone clinical trials. In conjunction with these discovery programs, the synthesis and biological testing of various metabolites associated with these clinical targets were actively pursued. We now report the results of our synthetic efforts and the corresponding biological data generated for several of the metabolites of WAY-151932 and CL-347985 (Lixivaptan).

Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Publishing Authors By Initials

AJ Molinari,EJ Trybulski,J Bagli,S Croce,J Considine,J Qi,K Ali,W Demaio,L Lihotz,D Cochran,AJ Molinari,EJ Trybulski,J Bagli,S Croce,J Considine,J Qi,K Ali,W Demaio,L Lihotz,D Cochran,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Bioorganic & medicinal chemistry letters

VOLUME: 17

Page Numbers: 5796-800

Journal Abbreviation: Bioorg. Med. Chem. Lett.

ISSN: 0960-894X

DAY: 28

MONTH: 08

YEAR: 2007

Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9107377

Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.

AFFILIATION: Chemical and Screening Sciences, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA. Molinaa@wyeth.com

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Bioorg Med Chem Lett

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan Related Publications

• "Cyclic hyperalimentation" - an optimal technique for preservation of visceral protein mass.
• 1-3 connectivity lithium niobate composites for high temperature operation.
• A clinical and electrophysiological investigation of anterior transposition for ulnar neuropathy at the elbow.
• A feasibility study evaluating rhBMP-2/absorbable collagen sponge device for local alveolar ridge preservation or augmentation.
• A rapidly inducible DNA-binding activity which binds upstream of the c-fos proto-oncogene.
• Addressing youth and family vulnerability: empowerment in an ecological context.
• Bone apposition around two different sandblasted and acid-etched titanium implant surfaces: a histomorphometric study in canine mandibles.
• Cisapride in functional dyspepsia: a double-blind, placebo-controlled randomized trial in general practice patients.
• Current perspectives in the diagnosis and treatment of urinary stone disease.
• Drug use, drug severity, and help-seeking behaviors of lesbian and bisexual women.
• Enhanced implant stability with a chemically modified SLA surface: a randomized pilot study.
• Error and patient safety: ethical analysis of cases in occupational and physical therapy practice.
• Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.
• Islet-cell tumour of pancreas; report of a case.
• Palladium-catalyzed intramolecular chloroamination of alkenes.
• Papillary tumor of the pineal region.
• Pathology quiz case 2: steatocystoma multiplex.
• Phase and magnitude in normalized images.
• Quality assessment and improvement: what radiologists do and think.
• RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffin-embedded tissues of melanoma and nevi.
• Room temperature palladium-catalyzed intramolecular hydroamination of unactivated alkenes.
• SCATTERED RADIATION FROM A COBALT-60 SOURCE IN A BRICK STRUCTURE. TECHN DOCUM REP NO. SAM-TDR-64-14.
• Sentinel node biopsy: not only a staging tool?
• State of the science on implant dentistry: a workshop developed using an evidence-based approach.
• Surgical principles in the care of the severely burned.
• The SAM hgh level cobalt-60 irradiation facility. SAM-TR-65-65.
• The mitotic regulator survivin binds as a monomer to its functional interactor borealin.
• Use of Inhaled Heparin/N-acetylcystine in Inhalation Injury: Does it help?
• Vesicular Jarisch-Herxheimer reaction.
• [Water supply in the urbanization planning]